BLTE:NASDAQ, Belite Bio, Inc

BLTE stock overview

Belite Bio, Inc (BLTE:NASDAQ) closed at $147.33 on October 23, 2026, down 1.96% on the day. The stock trades 26.3% below its 52-week high of $200.00 and 62.3% above its 52-week low of $90.77. Over the past year, it gained 58.7%. Belite Bio, Inc is part of the Health Care sector.

Key figures

Price
$147.33
Day change
-1.96%
Volume
49,853
Average volume
183,856
Market cap
5B+
52-week range
$90.77 – $200.00
50-day average
$163.38
200-day average
$160.67

Price action over the past year

In 252 trading sessions since October 23, 2025, BLTE closed higher on 124 days (49%). Its best day was September 4, 2026 (+13.16%) and its worst was November 11, 2025 (-9.87%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

BLTE news

About Belite Bio, Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Similar stocks

Find more stocks like BLTE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.